Luspatercept is especially effective in MDS-RS or SF3B1-mutated MDS [77% vs 40% in non-mutated (73)] possibly by alleviating the impact from proinflammatory microenvironment (74). The gene discussed is SF3B1; the disease is myelodysplastic syndrome.